Lisa B Dixon1, Howard H Goldman1, Melanie E Bennett1, Yuanjia Wang1, Karen A McNamara1, Sapna J Mendon1, Amy B Goldstein1, Chien-Wen J Choi1, Rufina J Lee1, Jeffrey A Lieberman1, Susan M Essock1. 1. Dr. Dixon, Ms. Mendon, Ms. Choi, Dr. Lieberman, and Dr. Essock are with the New York State Psychiatric Institute, New York City (e-mail: dixonli@nyspi.columbia.edu ). Dr. Dixon, Dr. Lieberman, and Dr. Essock are also with the Department of Psychiatry, Columbia University College of Physicians and Surgeons. Dr. Goldman, Dr. Bennett, and Dr. McNamara are with the Department of Psychiatry, University of Maryland School of Medicine, Baltimore. Dr. Wang is with the Division of Biostatistics, Mailman School of Public Health, Columbia University, New York City. Dr. Goldstein is with the Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, Maryland. Dr. Lee is with the Silberman School of Social Work, Hunter College, City University of New York, New York City. This article is part of a special section on RAISE and other early intervention services. Marcela Horvitz-Lennon, M.D., M.P.H., served as guest editor of the special section.
Abstract
OBJECTIVE: The RAISE (Recovery After an Initial Schizophrenia Episode) Connection Program Implementation and Evaluation Study developed tools necessary to implement and disseminate an innovative team-based intervention designed to promote engagement and treatment participation, foster recovery, and minimize disability among individuals experiencing early psychosis. This article describes the treatment model and reports on service utilization and outcomes. It was hypothesized that individuals' symptoms and functioning would improve over time. METHODS: A total of 65 individuals in RAISE Connection Program treatment across two sites (Baltimore and New York City) were enrolled and received services for up to two years. Primary outcomes, including social and occupational functioning and symptoms, were evaluated. Trajectories for individuals' outcomes over time were examined with linear and quadratic mixed-effects models with repeated measures. RESULTS: Measures of occupational and social functioning improved significantly over time, symptoms declined, and rates of remission improved. Visits were most frequent during the first three months, with a mean±SD of 23.2±11.5 unduplicated staff encounters per quarter. Such encounters decreased to 8.8±5.2 in the final quarter of year 2. CONCLUSIONS: The overall project was successful in that the treatment program was delivered and tools useful to other clinical settings were produced. The strengths of this study lie in the demonstrated feasibility of delivering the coordinated specialty care model and the associated high rates of engagement among individuals who are typically difficult to engage in treatment. Notwithstanding the lack of a built-in comparison group, participant outcomes were promising, with improvements comparable to those seen with other successful interventions.
OBJECTIVE: The RAISE (Recovery After an Initial Schizophrenia Episode) Connection Program Implementation and Evaluation Study developed tools necessary to implement and disseminate an innovative team-based intervention designed to promote engagement and treatment participation, foster recovery, and minimize disability among individuals experiencing early psychosis. This article describes the treatment model and reports on service utilization and outcomes. It was hypothesized that individuals' symptoms and functioning would improve over time. METHODS: A total of 65 individuals in RAISE Connection Program treatment across two sites (Baltimore and New York City) were enrolled and received services for up to two years. Primary outcomes, including social and occupational functioning and symptoms, were evaluated. Trajectories for individuals' outcomes over time were examined with linear and quadratic mixed-effects models with repeated measures. RESULTS: Measures of occupational and social functioning improved significantly over time, symptoms declined, and rates of remission improved. Visits were most frequent during the first three months, with a mean±SD of 23.2±11.5 unduplicated staff encounters per quarter. Such encounters decreased to 8.8±5.2 in the final quarter of year 2. CONCLUSIONS: The overall project was successful in that the treatment program was delivered and tools useful to other clinical settings were produced. The strengths of this study lie in the demonstrated feasibility of delivering the coordinated specialty care model and the associated high rates of engagement among individuals who are typically difficult to engage in treatment. Notwithstanding the lack of a built-in comparison group, participant outcomes were promising, with improvements comparable to those seen with other successful interventions.
Authors: Alicia Lucksted; Susan M Essock; Jennifer Stevenson; Sapna J Mendon; Ilana R Nossel; Howard H Goldman; Amy B Goldstein; Lisa B Dixon Journal: Psychiatr Serv Date: 2015-04-15 Impact factor: 3.084
Authors: Keith H Nuechterlein; Kenneth L Subotnik; Luana R Turner; Joseph Ventura; Deborah R Becker; Robert E Drake Journal: Psychiatr Rehabil J Date: 2008
Authors: Leslie Marino; Ilana Nossel; Jean C Choi; Keith Nuechterlein; Yuanjia Wang; Susan Essock; Melanie Bennett; Karen McNamara; Sapna Mendon; Lisa Dixon Journal: J Nerv Ment Dis Date: 2015-05 Impact factor: 2.254
Authors: Joshua Ray Tanzer; Colleen A Redding; Irena Mikhalyuk; Bridget Bennett; Barbara Lamoureux; Denise Achin; Shayna Bassett; Rosemarie Martin; L A R Stein Journal: Community Ment Health J Date: 2021-01-12
Authors: Iruma Bello; Rufina Lee; Igor Malinovsky; Liza Watkins; Ilana Nossel; Thomas Smith; Hong Ngo; Michael Birnbaum; Leslie Marino; Lloyd I Sederer; Marleen Radigan; Gyojeong Gu; Susan Essock; Lisa B Dixon Journal: Psychiatr Serv Date: 2016-12-15 Impact factor: 3.084
Authors: Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger Journal: Nat Rev Drug Discov Date: 2016-03-04 Impact factor: 84.694
Authors: Keith H Nuechterlein; Kenneth L Subotnik; Joseph Ventura; Luana R Turner; Michael J Gitlin; Denise Gretchen-Doorly; Deborah R Becker; Robert E Drake; Charles J Wallace; Robert P Liberman Journal: Psychol Med Date: 2019-01-04 Impact factor: 7.723
Authors: Joseph S DeLuca; Nicole D Andorko; Doha Chibani; Samantha Y Jay; Pamela J Rakhshan Rouhakhtar; Emily Petti; Mallory J Klaunig; Elizabeth C Thompson; Zachary B Millman; Kathleen M Connors; LeeAnn Akouri-Shan; John Fitzgerald; Samantha L Redman; Caroline Roemer; Miranda A Bridgwater; Jordan E DeVylder; Cheryl A King; Steven C Pitts; Shauna P Reinblatt; Heidi J Wehring; Kristin L Bussell; Natalee Solomon; Sarah M Edwards; Gloria M Reeves; Robert W Buchanan; Jason Schiffman Journal: J Psychother Integr Date: 2020-06
Authors: Michael Groff; Eric Latimer; Ridha Joober; Srividya N Iyer; Norbert Schmitz; Sherezad Abadi; Amal Abdel-Baki; Nicola Casacalenda; Howard C Margolese; G Eric Jarvis; Ashok Malla Journal: Schizophr Bull Date: 2021-03-16 Impact factor: 9.306